Wutah pendapatan taunan sajrone rolas wulan kepungkur: Silo Pharma Inc. (SILO)

Silo Pharma, Inc. (SILO) is focusing its development vector on creating psilocybin transdermal patches to combat neuropsychiatric pathologies. The company focuses on restoring cognitive functions in Alzheimer's disease using low doses of substances. Revenue is based on nasal delivery systems for the therapy of PTSD and dementia. The year-over-year product sales volume dynamics for the TTM demonstrate the asset's market position, where the current status is -49.90.
Silo Pharma - rincian analitis lan metrik utama (SILO)

The selection of high-quality issuers is based on an analysis of cash flow dynamics and business scaling rates via key multiples. This relative change in rolling year revenue compared to the same period last year captures the sales growth rate over the last twelve months, which is critical for Silo Pharma, Inc. (SILO) as it transitions from R&D to drug commercialization under strict FDA regulation and intellectual property protection.